Description
BIOFIRE REAGENTS
First action · last action
2025-10-01 · 2025-10-01
Transactions
1
First transaction's obligation
$734,237
Base + all options value (sum of deltas)
$734,237
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
36F79724D0020
NAICS
325413 · IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2025-10-01+$734,237= $734,237
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2025-10-01 | +$734,237 | $734,237 | BIOFIRE REAGENTS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI HCNVCMEG9NL6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25926F0276 | NETWORK CONTRACT OFFICE 19 (36C259) · 6640 · LABORATORY EQUIPMENT AND SUPPLIES | $60,940 | FY2026 |
| 36C25726N0441 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6632 · ANALYSIS INSTRUMENTS, MEDICAL LABORATORY USE | $122,631 | FY2026 |
| 36C25726D0091 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6632 · ANALYSIS INSTRUMENTS, MEDICAL LABORATORY USE | $0 | FY2026 |
| 36C26226N0903 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $67,946 | FY2026 |
| 36C24926N0666 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $982,841 | FY2026 |
| 36C24126N0842 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $310,739 | FY2026 |
Other recipients under 6550 from 249-NETWORK CONTRACT OFFICE 9 (36C249) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24926A0041 | ROCHE DIAGNOSTICS CORPORATION | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $0 | FY2026 |
| 36C24926N0558 | ROCHE DIAGNOSTICS CORPORATION | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $480,738 | FY2026 |
| 36C24926N0423 | ABBOTT MOLECULAR INC. | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $471,122 | FY2026 |
| 36C24926N0334 | IMMUNO MYCOLOGIES INC | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $118,846 | FY2026 |
| 36C24926N0424 | GENBEN LIFESCIENCES CORP | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $11,960 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24926N0198_3600_36F79724D0020_3600 · retrieved 2026-09-26.